These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32947557)

  • 1. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization.
    Chantharit P; Tantasawat M; Kasai H; Tanigawara Y
    Ther Drug Monit; 2020 Dec; 42(6):872-879. PubMed ID: 32947557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension via Enteral Feeding Tube in Intensive Care Unit Patients.
    Tanaka R; Eto D; Goto K; Ohchi Y; Yasuda N; Suzuki Y; Tatsuta R; Kitano T; Itoh H
    Biol Pharm Bull; 2021; 44(5):737-741. PubMed ID: 33952830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.
    Liu X; Su H; Tong J; Chen J; Yang H; Xiao L; Hu J; Zhang L
    Medicine (Baltimore); 2017 Oct; 96(42):e8039. PubMed ID: 29049191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the
    Ling J; Yang X; Dong L; Jiang Y; Zou S; Hu N
    Front Pharmacol; 2024; 15():1455721. PubMed ID: 39228522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of voriconazole and its alteration by Candida albicans infection in silkworms.
    Yasu T; Matsumoto Y; Sugita T
    J Antibiot (Tokyo); 2021 Jul; 74(7):443-449. PubMed ID: 34045695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study.
    Miyakawa-Tanaka K; Suzuki J; Hirasawa Y; Nakamura S; Takeda K; Narumoto O; Matsui H
    J Infect Chemother; 2023 Jul; 29(7):683-687. PubMed ID: 36965708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of Aspergillus empyema using combined intrathoracic and intravenous administration of voriconazole: A case report.
    Takatsuka H; Yamazaki S; Watanabe A; Yokoyama I; Suzuki T; Kamei K; Ishii I
    J Infect Chemother; 2020 Aug; 26(8):847-850. PubMed ID: 32414688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of
    Ebrahimpour S; Namazi S; Mohammadi M; Nikbakht M; Hadjibabaie M; Masoumi HT; Ghavamzadeh A
    J Res Pharm Pract; 2017; 6(3):151-157. PubMed ID: 29026840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of different pharmacokinetic models to describe and predict pharmacokinetics of voriconazole in magellanic penguins following oral administration.
    Parsley RA; Mutlow AG; Hansted J; Taverne FJ; Tell LA; Gehring R
    J Vet Pharmacol Ther; 2019 Jan; 42(1):74-84. PubMed ID: 30175535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.